Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Lung Cancer

Free Subscription 23.06.2025 1 Ann Surg Oncol 3 Ann Thorac Surg 1 BMC Cancer 1 Cancer 1 Cancer Chemother Pharmacol 2 Cancer Lett 1 Cancer Res 3 Clin Lung Cancer 1 Eur J Cancer 1 Eur Respir J 1 Int J Cancer 1 J Cancer Res Clin Oncol 1 J Thorac Oncol 1 Lancet 1 Lancet Oncol 2 Lung Cancer 1 Nat Med 1 Oncogene 4 PLoS One 1 Proc Natl Acad Sci U S A

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Ann Surg Oncol

1. KHAN AA, Shah SK, Basu S, Alex GC, et al
   ASO Visual Abstract: Thoracic Adipose Volume is Associated with Occult Nodal Disease- and Disease-Free Survival in Females with Clinically Node Negative Non-Small Cell Lung Cancer.
   Ann Surg Oncol. 2025 Jun 14. doi: 10.1245/s10434-025-17634.
   PubMed        
   
   

   
   Ann Thorac Surg

2. WEN J, Dong Y, Chen T, Wu J, et al
   Prognostic Impact and Recurrence Pattern of KRAS G12C Mutation in Surgically Resected Non-Small Cell Lung Cancer.
   Ann Thorac Surg. 2025 Jun 16:S0003-4975(25)00526.
   PubMed         Abstract available
   
   
3. RATHORE K
   Globally Recognised Difficulties in Lung Cancer Care Management That May Lead to Poor Outcomes.
   Ann Thorac Surg. 2025 Jun 16:S0003-4975(25)00527.
   PubMed        
   
   
4. TOMPKINS AK, Azuma M, Erkmen CP
   From Broadening to Optimizing: Refining Approach to Lung Cancer Screening Criteria.
   Ann Thorac Surg. 2025 Jun 13:S0003-4975(25)00518.
   PubMed        
   
   

   
   BMC Cancer

5. CHEN H, Yu Y, Zhu S, Zhao J, et al
   Correction: Impact of metabolic and nutritional disorders on the synergy between radiotherapy and immunotherapy in non-small-cell lung cancer.
   BMC Cancer. 2025;25:1019.
   PubMed        
   
   

   
   Cancer

6. LEAL TA, Wang Y, Dowlati A, Chay CH, et al
   Randomized phase II clinical trial of cisplatin/carboplatin and etoposide (PE) alone or in combination with nivolumab as frontline therapy for extensive-stage small cell lung cancer (ES-SCLC): ECOG-ACRIN EA5161.
   Cancer. 2025;131:e35938.
   PubMed         Abstract available
   
   

   
   Cancer Chemother Pharmacol

7. LI H, Pu Z, Fang J
   Effect of Metformin on vascular endothelial injury in patients with non-small cell lung cancer treated with chemotherapy combined with bevacizumab.
   Cancer Chemother Pharmacol. 2025;95:59.
   PubMed         Abstract available
   
   

   
   Cancer Lett

8. CHEN H, Yu G, Lin H, Zhou XA, et al
   Loss of FTSJ3 promotes R-loop-associated DNA damage and facilitates chemosensitivity in lung cancer cells.
   Cancer Lett. 2025 Jun 13:217877. doi: 10.1016/j.canlet.2025.217877.
   PubMed         Abstract available
   
   
9. KHORRAMI M, Mutha P, Barrera C, Viswanathan VS, et al
   AI-based radiomic features predict outcomes and the added benefit of chemoimmunotherapy over chemotherapy in extensive stage small cell lung cancer: A multi-institutional study.
   Cancer Lett. 2025;628:217872.
   PubMed         Abstract available
   
   

   
   Cancer Res

10. SCORTEGAGNA M, Murad R, Bina P, Feng Y, et al
    Age-Associated Modulation of TREM1/2-Expressing Macrophages Promotes Melanoma Progression and Metastasis.
    Cancer Res. 2025 Mar 24. doi: 10.1158/0008-5472.CAN-24-4317.
    PubMed         Abstract available
    
    

    
    Clin Lung Cancer

11. WALIANY S, Hung YP, Rous FA, Luo F, et al
    Lung Carcinoid Tumors With Potentially Actionable Genomic Alterations and Responses to Targeted Therapies.
    Clin Lung Cancer. 2025;26:354-363.
    PubMed         Abstract available
    
    
12. RAKEDZON S, Mor E, Yechiel Y, Saiet Y, et al
    Correlation of PET-CT, Endobronchial Ultrasound Cytology and Surgical Biopsy in Patients with Non-Small Cell Lung Cancer Undergoing Curative Surgery.
    Clin Lung Cancer. 2025 May 18:S1525-7304(25)00103.
    PubMed         Abstract available
    
    
13. KRUITHOF PD, Brouns AJWM, Degens JHRJ, Hendriks LEL, et al
    Osimertinib Dose Optimization Guided by Therapeutic Drug Monitoring in Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Case series.
    Clin Lung Cancer. 2025 May 29:S1525-7304(25)00125.
    PubMed        
    
    

    
    Eur J Cancer

14. LAGUNA JC, Moreno L, Potrony M, Grau E, et al
    Prevalence and characteristics of lung cancer in families harboring Pathogenic Germline Variants in cancer predisposing genes: A 20-year retrospective analysis.
    Eur J Cancer. 2025;225:115571.
    PubMed         Abstract available
    
    

    
    Eur Respir J

15. SHEIKH M, Weiderpass E
    Lung cancer screening in Europe: a golden opportunity to address tobacco use through scalable, WHO-guided cessation interventions.
    Eur Respir J. 2025;65:2500124.
    PubMed        
    
    

    
    Int J Cancer

16. CHANG GC, Kapoor A, Lee CK, Su C, et al
    Optimizing management of stage IV EGFR mutant non-small cell lung cancer in Asia: An expert opinion.
    Int J Cancer. 2025 Jun 14. doi: 10.1002/ijc.35512.
    PubMed         Abstract available
    
    

    
    J Cancer Res Clin Oncol

17. WANG D, Qiu J, Li R, Tian H, et al
    Development and interpretation of machine learning-based prognostic models for predicting high-risk prognostic pathological components in pulmonary nodules: integrating clinical features, serum tumor marker and imaging features.
    J Cancer Res Clin Oncol. 2025;151:190.
    PubMed         Abstract available
    
    

    
    J Thorac Oncol

18. FUKUDA K, Nanjo S, Takeuchi S, Chakrabarti T, et al
    Targeting WEE1 to overcome ARID1A mutation-driven osimertinib resistance in EGFR-mutant lung cancer.
    J Thorac Oncol. 2025 Jun 13:S1556-0864(25)00766.
    PubMed         Abstract available
    
    

    
    Lancet

19. CHOUDHURY NJ, Garassino MC
    Lurbinectedin with atezolizumab maintenance therapy in extensive-stage small-cell lung cancer.
    Lancet. 2025;405:2104-2106.
    PubMed        
    
    

    
    Lancet Oncol

20. ZHOU C, Wang Z, Sun M, Cao L, et al
    Sugemalimab versus placebo, in combination with platinum-based chemotherapy, as first-line treatment of metastatic non-small-cell lung cancer (GEMSTONE-302): 4-year outcomes from a double-blind, randomised, phase 3 trial.
    Lancet Oncol. 2025 Jun 13:S1470-2045(25)00198.
    PubMed         Abstract available
    
    

    
    Lung Cancer

21. YANG R, Wang H, Liu D, Li W, et al
    Prevalence and prognostic significance of interstitial lung abnormalities in lung cancer: A meta-analysis.
    Lung Cancer. 2025;205:108458.
    PubMed         Abstract available
    
    
22. GEMELLI M, Cortinovis D, Carola G, Moretti L, et al
    Efficacy of immune checkpoint inhibitors (ICIs) in PD-L1 negative Non-Small Cell Lung Cancer (NSCLC) - A meta-analysis based on reconstructed individual participant data.
    Lung Cancer. 2025;205:108621.
    PubMed         Abstract available
    
    

    
    Nat Med

23. MA Y, Yang Y, Huang Y, Fang W, et al
    A B7H3-targeting antibody-drug conjugate in advanced solid tumors: a phase 1/1b trial.
    Nat Med. 2025;31:1949-1957.
    PubMed         Abstract available
    
    

    
    Oncogene

24. TAN X, Wu C, Banerjee P, Wang S, et al
    Dichotomous roles of ACBD3 in NSCLC growth and metastasis.
    Oncogene. 2025;44:2078-2090.
    PubMed         Abstract available
    
    

    
    PLoS One

25. XIE W, Zhang Z, Zhao D, Zhang Y, et al
    Cancer disrupts sex hormone-inflammation relationships: Analysis of ALI in males from NHANES 2007-2018.
    PLoS One. 2025;20:e0325796.
    PubMed         Abstract available
    
    
26. 
    Retraction: Blocking TLR2 Activity Attenuates Pulmonary Metastases of Tumor.
    PLoS One. 2025;20:e0326513.
    PubMed        
    
    
27. CUI Y, Liu Z
    AKR1C2 silencing promotes ferroptosis and inhibits proliferation, migration, and invasion in lung cancer cells.
    PLoS One. 2025;20:e0325995.
    PubMed         Abstract available
    
    
28. WANG X, Liu J, Li C, Duan H, et al
    Latent class analysis of depression among patients with non-small cell lung cancer after surgery: A cross-sectional study.
    PLoS One. 2025;20:e0324723.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

29. JEONG D, Park SH, Kim J, Kim H, et al
    Tumor-promoting UBR4 coordinates impaired mitophagy-associated senescence and lung adenocarcinoma pathogenesis.
    Proc Natl Acad Sci U S A. 2025;122:e2425015122.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.